Across TCGA pan-cancer cohorts, CNIH3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CNIH3 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CNIH3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CNIH3 expression acts as an unfavorable survival marker.
LUAD and READ are the cancer types where CNIH3 Mutation most reproducibly stratifies survival.